Clinical Trial Update: CTS2190 Phase I /II Clinical Study in Patients [Phase 1, Phase 2]

View source ↗

Summary

CTS2190 is a Phase 1/2 clinical study by CytosinLab Therapeutics evaluating CTS2190 in solid tumors, including pancreatic cancer, non-small cell lung cancer, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CTS2190

Snippet

Sponsor: CytosinLab Therapeutics Co., Ltd. | Conditions: Solid Tumors, Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING